TACR1 and cancer: Interestingly, cancer cells expressing higher levels of the truncated tachykinin receptor 1 (TACR1) isoform exhibit more important sensitivity to NK-1R inhibition which might enable the stratification of PDAC patients who could benefit from NK-1R-targeted therapies [149].